The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia
IGF2BP2 在 MLL 重排白血病中的作用和治疗潜力
基本信息
- 批准号:10464855
- 负责人:
- 金额:$ 57.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccountingAcute Myelocytic LeukemiaAcute Promyelocytic LeukemiaAdolescentAdultArsenic TrioxideBasic ScienceBinding ProteinsBiologyCellsChildhood LeukemiaChimeric ProteinsChromosome abnormalityComplexCytogeneticsDataDevelopmentExhibitsGene ExpressionGenerationsGenesGenetic TranscriptionGoalsHematopoietic NeoplasmsHematopoietic stem cellsKnowledgeLeadMLL-rearranged leukemiaMLLT3 geneMaintenanceMedicalMessenger RNAMixed-Lineage LeukemiaModificationMolecularMolecular AbnormalityOncogenicOutcomePathogenesisPathologicPathway interactionsPatientsPatternPharmacologyPlant RootsPlayPrognosisPromoter RegionsProteinsRNAReaderRelapseRoleSolidSubgroupSurvival RateTestingTherapeuticTherapeutic AgentsTherapeutic EffectTherapeutic InterventionToxic effectTranscriptTranslational ResearchTranslationsTreatment EfficacyTreatment FailureTretinoinacute myeloid leukemia cellbasebioprocesscancer typeeffective therapyimprovedinhibitorinsightleukemialeukemia treatmentnew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticsoverexpressionpharmacokinetics and pharmacodynamicsself-renewalside effectsmall molecule inhibitorstemsuccesst(821)(q22q22)targeted treatmenttherapeutically effectivetranslational medicinetumor
项目摘要
PROJECT SUMMARY (ABSTRACT):
Title: The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia.
Background: N6-methyladenosine (m6A) modification is the most abundant internal modification in
eukaryotic messenger RNAs (mRNAs) and plays roles in many normal bioprocesses. Evidence is emerging that
the aberration in m6A modification and the associated machinery also plays important roles in various types of
cancers. Acute myeloid leukemia (AML) is one of the most common forms of hematopoietic malignancies with various
cytogenetic and molecular abnormalities. The mixed-lineage leukemia (MLL)-rearranged (MLLr) AML is a common
and fatal subtype of AML, which accounts for 5%-10% of “de novo” AML cases and 10%-15% of therapy-related
leukemia (t-AML) cases. MLLr AML patients are associated with poor outcomes, with a 5-year overall survival
(OS) rate of ~30%. Therefore, there is a critical unmet medical need to develop improved therapeutics for
MLLr AML treatment. The leukemia stem/initiating cells (LSCs/LICs) are considered to be the root cause for the
treatment failure and relapse of AML. Collectively, it is critical to better understand the molecular mechanisms underlying
MLLr AML pathogenesis and LSC/LIC self-renewal, which may lead to the development of improved novel therapeutic
strategies to treat MLLr AML. Our preliminary data showed that IGF2BP2, which encodes an m6A reader, is specially
overexpressed in MLLr AML and its increased expression is associated with a poor prognosis in AML patients.
Our preliminary functional studies suggest that IGF2BP2 likely plays a critical oncogenic role as an m6A reader
in promoting MLLr AML pathogenesis. IGF2BP2 is also expressed at a significantly higher level in MLLr
LSCs/LICs compared to healthy hematopoietic stem/progenitor cells (HSPCs) and bulk MLLr AML cells, implying
a role of IGF2BP2 in MLLr LSC/LIC self-renewal. In addition, we have developed a potent inhibitor (namely
CWI1-2) that targets IGF2BP2 directly and exhibits high anti-leukemia efficacy as shown in our preliminary
studies.
Hypothesis: IGF2BP2 plays an essential role in MLLr AML pathogenesis and LSC/LIC self-renewal, and
that pharmacological inhibition of IGF2BP2 can lead to effective treatment of MLLr AML.
Specific Aims: 1) Determine the role of IGF2BP2 in MLLr AML pathogenesis and LSC/LIC self-renewal; 2)
Decipher the molecular mechanism underlying the role of IGF2BP2 in MLLr AML; and 3) Assess the therapeutic
potential of pharmacologically targeting IGF2BP2 in treating MLLr AML.
Potential Impact: Our proposed studies are of high novelty and high significance in both basic research and
translational medicine, which will substantially advance our understanding of the biology of MLLr leukemia, and
may also result in the development of effective novel therapeutics for the treatment of MLLr leukemia.
项目概要(摘要):
标题:IGF2BP2 在 MLL 重排白血病中的作用和治疗潜力。
背景:N6-甲基腺苷(m6A)修饰是最丰富的内部修饰
真核生物信使 RNA (mRNA) 在许多正常生物过程中发挥作用。越来越多的证据表明
m6A 修饰中的像差和相关机制也在各种类型的
癌症。急性髓系白血病(AML)是最常见的造血系统恶性肿瘤之一,可导致多种疾病
细胞遗传学和分子异常。混合谱系白血病 (MLL) 重排 (MLLr) AML 是一种常见的
AML 的致命亚型,占“新发”AML 病例的 5%-10%,占治疗相关病例的 10%-15%
白血病(t-AML)病例。 MLLr AML 患者预后不良,总体生存期为 5 年
(OS) 率约为 30%。因此,开发改进的治疗方法迫切需要满足未满足的医疗需求。
MLLr AML 治疗。白血病干细胞/起始细胞(LSC/LIC)被认为是白血病的根本原因。
AML 治疗失败和复发。总的来说,更好地理解潜在的分子机制至关重要
MLLr AML 发病机制和 LSC/LIC 自我更新,这可能导致改进的新型治疗方法的开发
治疗 MLLr AML 的策略。我们的初步数据表明,编码 m6A 阅读器的 IGF2BP2 是专门
MLLr AML 中过度表达,其表达增加与 AML 患者的不良预后相关。
我们的初步功能研究表明 IGF2BP2 可能作为 m6A 阅读器发挥着关键的致癌作用
促进 MLLr AML 发病机制。 IGF2BP2 在 MLLr 中的表达水平也显着升高
LSC/LIC 与健康造血干/祖细胞 (HSPC) 和大量 MLLr AML 细胞相比,这意味着
IGF2BP2 在 MLLr LSC/LIC 自我更新中的作用。此外,我们还开发了一种有效的抑制剂(即
CWI1-2)直接靶向 IGF2BP2,并表现出高抗白血病功效,如我们的初步结果所示
研究。
假设:IGF2BP2 在 MLLr AML 发病机制和 LSC/LIC 自我更新中发挥重要作用,并且
药物抑制 IGF2BP2 可以有效治疗 MLLr AML。
具体目标: 1) 确定IGF2BP2在MLLr AML发病机制和LSC/LIC自我更新中的作用; 2)
破译IGF2BP2在MLLr AML中作用的分子机制; 3) 评估治疗效果
药物靶向 IGF2BP2 在治疗 MLLr AML 中的潜力。
潜在影响:我们提出的研究在基础研究和研究方面都具有很高的新颖性和重要意义。
转化医学,这将大大增进我们对 MLLr 白血病生物学的理解,以及
还可能导致开发出治疗 MLLr 白血病的有效新疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianjun Chen其他文献
Jianjun Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianjun Chen', 18)}}的其他基金
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
TET2介导的白血病微环境中的表观转录组调控
- 批准号:
10801348 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia
IGF2BP2 在 MLL 重排白血病中的作用和治疗潜力
- 批准号:
10579300 - 财政年份:2022
- 资助金额:
$ 57.35万 - 项目类别:
The function and underlying mechanism of TET1 in myelodysplastic syndromes
TET1在骨髓增生异常综合征中的功能及机制
- 批准号:
10549295 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别:
The function and underlying mechanism of TET1 in myelodysplastic syndromes
TET1在骨髓增生异常综合征中的功能及机制
- 批准号:
10304942 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别:
The function and underlying mechanism of TET1 in myelodysplastic syndromes
TET1在骨髓增生异常综合征中的功能及机制
- 批准号:
9914855 - 财政年份:2020
- 资助金额:
$ 57.35万 - 项目类别:
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML
METTL3/METTL14介导的RNA修饰在AML发病及耐药中的作用及机制
- 批准号:
10329928 - 财政年份:2019
- 资助金额:
$ 57.35万 - 项目类别:
Targeting FTO to treat acute myeloid leukemia
靶向FTO治疗急性髓系白血病
- 批准号:
10058254 - 财政年份:2019
- 资助金额:
$ 57.35万 - 项目类别:
Targeting FTO to treat acute myeloid leukemia
靶向FTO治疗急性髓系白血病
- 批准号:
10531853 - 财政年份:2019
- 资助金额:
$ 57.35万 - 项目类别:
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML
METTL3/METTL14介导的RNA修饰在AML发病及耐药中的作用及机制
- 批准号:
9765111 - 财政年份:2019
- 资助金额:
$ 57.35万 - 项目类别:
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML
METTL3/METTL14介导的RNA修饰在AML发病及耐药中的作用及机制
- 批准号:
10558640 - 财政年份:2019
- 资助金额:
$ 57.35万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 57.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 57.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 57.35万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 57.35万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 57.35万 - 项目类别:














{{item.name}}会员




